Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.

Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R.

J Urol. 2013 Jan;189(1 Suppl):S117-21. doi: 10.1016/j.juro.2012.11.031.

PMID:
23234615
2.

Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.

Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R.

J Urol. 2009 Dec;182(6):2831-5. doi: 10.1016/j.juro.2009.08.030. Epub 2009 Oct 17.

PMID:
19837428
3.

Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.

Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K.

Neurourol Urodyn. 2010 Apr;29(4):558-62. doi: 10.1002/nau.20802.

PMID:
19693954
4.

Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.

Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H.

Neurourol Urodyn. 2013 Nov;32(8):1123-7. doi: 10.1002/nau.22349. Epub 2013 Jul 17.

PMID:
23861329
5.
6.

Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.

Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H.

Int J Urol. 2014 Dec;21(12):1258-62. doi: 10.1111/iju.12570. Epub 2014 Jul 15.

7.

Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K.

Eur Urol. 2008 Aug;54(2):419-26. doi: 10.1016/j.eururo.2008.02.017. Epub 2008 Feb 25.

PMID:
18325657
8.

Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.

Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE.

J Urol. 2013 Oct;190(4):1320-7. doi: 10.1016/j.juro.2013.05.062. Epub 2013 May 30.

PMID:
23727415
9.

Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction.

Rosario DJ, Woo H, Potts KL, Cutinha PE, Hastie KJ, Chapple CR.

Br J Urol. 1997 Oct;80(4):579-86.

PMID:
9352697
10.
12.
14.

Repeated pressure-flow studies in the evaluation of bladder outlet obstruction due to benign prostatic enlargement. Finasteride Urodynamics Study Group.

Tammela TL, Schäfer W, Barrett DM, Abrams P, Hedlund H, Rollema HJ, Matos-Ferreira A, Nordling J, Bruskewitz R, Miller P, Kirby R, Andersen JT, Jacobsen C, Gormley GJ, Malice MP, Bach MA.

Neurourol Urodyn. 1999;18(1):17-24.

PMID:
10090123
15.

Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases infravesical obstruction: results in 134 patients after 1 year.

Thalmann GN, Graber SF, Bitton A, Burkhard FC, Gruenig O, Studer UE.

J Urol. 1999 Aug;162(2):387-93.

PMID:
10411044
16.

What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study.

Matsukawa Y, Hattori R, Sassa N, Yamamoto T, Gotoh M.

Neurourol Urodyn. 2013 Mar;32(3):266-70. doi: 10.1002/nau.22286. Epub 2012 Aug 20.

PMID:
22907775
18.

Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study.

Shimizu N, Minami T, Sugimoto K, Saito Y, Yamamoto Y, Hayashi T, Tsuji H, Nozawa M, Yoshimura K, Ishii T, Uemura H, Nakamatsu K.

World J Urol. 2014 Dec;32(6):1423-32. doi: 10.1007/s00345-014-1239-z. Epub 2014 Jan 17.

PMID:
24435207
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk